Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Archives of Oto-Rhino-Laryngology
Published in: European Archives of Oto-Rhino-Laryngology 12/2016

01-12-2016 | Review Article

Perspectives in chemosensitivity and chemoresistance assays and their implementation in head and neck cancer

Published in: European Archives of Oto-Rhino-Laryngology | Issue 12/2016

Login to get access

Abstract

Therapeutic options for patients with head and neck squamous cell carcinoma include surgery, radiation and chemotherapy. The latter plays a major role in the treatment selection of recurrent, metastatic or therapy resistant tumours, these being some of the major challenges in head and neck oncology. For these patients, chemosensitivity and chemoresistance assays would be paramount to identify their individual therapy options. In this review, seven common assays will be described and discussed in the context of several studies. Further, a new assay will also be presented, currently being validated in a European Union funded project. Comparisons will be drawn to evaluate the sensitivity and specificity of these assays in identifying individual treatment options, and their potential implementation in head and neck malignancies will be discussed. There is an unmet demand for the development of ex vivo diagnostic tools that may predict response in head and neck cancer on the way towards an individualized treatment for these patients.
Literature
1.
Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108CrossRefPubMed
2.
Houchens DP, Ovejera AA, Hrsg (1978) Proceedings of the symposium on the use of athymic (nude) mice in Cancer research, 1977. Fischer, New York
3.
Petty RD, Sutherland LA, Hunter EM et al (1995) Comparison of MTT and ATP-based assays for the measurement of viable cell number. J Biolumin Chemilumin 10:29–34CrossRefPubMed
4.
Maenpaa JU, Heinonen E, Hinkka SM et al (1995) The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial. Gynecol Oncol 57:294–298CrossRefPubMed
5.
Price KAR, Cohen EE (2012) Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol 13:35–46CrossRefPubMed
6.
Burstein HJ, Mangu PB, Somerfield MR et al (2011) American society of clinical oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol 29:3328–3330CrossRefPubMed
7.
Whitehouse PA, Knight LA, Di Nicolantonio F et al (2003) Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumour chemosensitivity assay (ATP-TCA). Anticancer Drugs 14:369–375CrossRefPubMed
8.
9.
Ang KK, Sturgis EM (2012) Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Semin Radiat Oncol 22:128–142CrossRefPubMed
10.
11.
Mirghani H, Amen F, Moreau F et al (2014) Oropharyngeal cancers: relationship between epidermal growth factor receptor alterations and human papillomavirus status. Eur J Cancer (Oxford, England: 1990) 50:1100–1111
12.
Samson DJ, Seidenfeld J, Ziegler K et al (2004) Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 22:3618–3630CrossRefPubMed
13.
Wu B, Zhu J, Zhang Y et al (2008) Predictive value of MTT assay as an in vitro chemosensitivity testing for gastric cancer: one institution’s experience. World J Gastroenterol 14:3064–3068CrossRefPubMedPubMedCentral
14.
Cree IA, Pazzagli M, Mini E et al (1995) Methotrexate chemosensitivity by ATP luminescence in human leukemia cell lines and in breast cancer primary cultures: comparison of the TCA-100 assay with a clonogenic assay. Anticancer Drugs 6:398–404CrossRefPubMed
15.
Mehta RS, Bornstein R, Yu IR et al (2001) Breast cancer survival and in vitro tumour response in the extreme drug resistance assay. Breast Cancer Res Treat 66:225–237CrossRefPubMed
16.
Von Hoff DD, Kronmal R, Salmon SE et al (1991) A southwest oncology group study on the use of a human tumour cloning assay for predicting response in patients with ovarian cancer. Cancer 67:20–27CrossRef
17.
Suonio E, Lipponen P, Maenpaa J et al (1997) Mitotic index in the subrenal capsule assay as an indicator of the chemosensitivity of ovarian cancer. Cancer Chemother Pharmacol 41:15–21CrossRefPubMed
18.
Shaw GL, Gazdar AF, Phelps R et al (1996) Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer. J Cell Biochem Suppl 24:173–185CrossRefPubMed
19.
Cortazar P, Gazdar AF, Woods E et al (1997) Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing. Clin Cancer Res 3:741–747PubMed
20.
Maurer HR, Ali-Osman F (1981) Tumour stem cell cloning in agar-containing capillaries. Naturwissenschaften 68:381–383CrossRefPubMed
21.
Ali-Osman F, Beltz PA (1988) Optimization and characterization of the capillary human tumour clonogenic cell assay. Cancer Res 48:715–724PubMed
22.
Von Hoff DD, Sandbach JF, Clark GM et al (1990) Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst 82:110–116CrossRef
23.
Weisenthal LM, Marsden JA, Dill PL et al (1983) A novel dye exclusion method for testing in vitro chemosensitivity of human tumours. Cancer Res 43:749–757PubMed
24.
Weisenthal LM, Dill PL, Kurnick NB et al (1983) Comparison of dye exclusion assays with a clonogenic assay in the determination of drug-induced cytotoxicity. Cancer Res 43:258–264PubMed
25.
Andreotti PE, Cree IA, Kurbacher CM et al (1995) Chemosensitivity testing of human tumours using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 55:5276–5282PubMed
26.
Chen F, Cushion MT (1994) Use of an ATP bioluminescent assay to evaluate viability of Pneumocystis carinii from rats. J Clin Microbiol 32:2791–2800PubMedPubMedCentral
27.
Ling Z, Qi C, Lu X et al (2012) Heterogeneity of chemosensitivity in esophageal cancer using ATP-tumour chemosensitivity assay. Acta Pharmacol Sin 33:401–406CrossRefPubMedPubMedCentral
28.
Sharma S, Neale MH, Di Nicolantonio F et al (2003) Outcome of ATP-based tumour chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer 3:19CrossRefPubMedPubMedCentral
29.
Meyer T, Nelstrop AE, Mahmoudi M et al (2001) Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer. Ann Oncol 12:1705–1709CrossRefPubMed
30.
Kern DH, Drogemuller CR, Kennedy MC et al (1985) Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumours. Cancer Res 45:5436–5441PubMed
31.
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63CrossRefPubMed
32.
Furukawa T, Kubota T, Watanabe M et al (1992) High in vitro-in vivo correlation of drug response using sponge-gel-supported three-dimensional histoculture and the MTT end point. Int J Cancer J Int du Cancer 51:489–498CrossRef
33.
Furukawa T, Kubota T, Hoffman RM (1995) Clinical applications of the histoculture drug response assay. Clin Cancer Res 1:305–311PubMed
34.
Bogden AE, Kelton DE, Cobb WR, Esber HJ (1978) A rapid screening method for testing chemotherapeutic agents against human tumour xenografts. In: Houchens DP, Ovejera AA (eds) Proceedings of the symposium on the use of athymic (nude) mice in Cancer research, 1977. Fischer, New York
35.
Singh B, Li R, Xu L et al (2002) Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 24:437–442CrossRefPubMed
36.
Hasegawa Y, Goto M, Hanai N et al (2007) Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer. Oral Oncol 43:749–756CrossRefPubMed
37.
38.
Hoffmann TK, Sonkoly E, Hauser U et al (2008) Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma. Oral Oncol 44:1100–1109CrossRefPubMed
39.
Martens-de Kemp SR, Dalm SU, Wijnolts FMJ et al (2013) DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells. PLoS ONE 8:e61555CrossRefPubMedPubMedCentral
40.
Erjala K, Raitanen M, Kulmala J et al (2007) Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol 133:169–176CrossRefPubMed
41.
Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. New Engl J Med 359:1116–1127CrossRefPubMed
42.
Seiwert TY, Haddad RI, Gupta S et al (2015) Antitumour activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): preliminary results from KEYNOTE-012 expansion cohort. ASCO Meet Abstr 33:LBA6008
43.
Dollner R, Granzow C, Helmke BM et al (2004) The impact of stromal cell contamination on chemosensitivity testing of head and neck carcinoma. Anticancer Res 24:325–331PubMed
44.
Dollner R, Granzow C, Neudert M et al (2006) Ex vivo chemosensitivity of head and neck carcinoma to cytostatic drug combinations. Anticancer Res 26:1651–1655PubMed
45.
Bogden AE, Von Hoff DD (1984) Comparison of the human tumour cloning and subrenal capsule assays. Cancer Res 44:1087–1090PubMed
46.
Rhedin AS, Tidefelt U, Jonsson K et al (1993) Comparison of a bioluminescence assay with differential staining cytotoxicity for cytostatic drug testing in vitro in human leukemic cells. Leuk Res 17:271–276CrossRefPubMed
47.
48.
Broder GR, Birtwell SW, Hagel G, Thastrup O, Morgan H, Roach PL (2011) Multiplex bioassays using a suspension array platform; towards the high throughput screening of drugs targeting cancer stem cells. In: Verpoorte S, Hrsg (eds) 14th International Conference on Miniaturized Systems for Chemistry and Life Sciences 2010. (MicroTAS 2010): Groningen, The Netherlands, 3–7 October 2010. San Diego, Calif., Red Hook, NY: Chemical and Biological Microsystems Society; Printed from e-media with permission by Curran Associates, Inc., vol c2010, pp 185–1387
49.
Metadata
Title
Perspectives in chemosensitivity and chemoresistance assays and their implementation in head and neck cancer
Publication date
01-12-2016
Published in
European Archives of Oto-Rhino-Laryngology / Issue 12/2016
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-015-3893-1

Other articles of this Issue 12/2016

European Archives of Oto-Rhino-Laryngology 12/2016 Go to the issue

Head and Neck

Articulation handicap index: an instrument for quantifying psychosocial consequences of impaired articulation

Miscellaneous

Calculating annoyance: an option to proof efficacy in ENT treatment of snoring?

Head and Neck

The effect of preoperative neutrophil, platelet and lymphocyte counts on local recurrence and survival in early-stage tongue cancer

Miscellaneous

The admission patterns of octogenerians nonagenerians and centenarians to the Department of Otoloaryngology

Otology

Predisposing factors for adverse skin reactions with percutaneous bone anchored hearing devices implanted with skin reduction techniques

Head and Neck

Gender-specific risk factors in post-tonsillectomy hemorrhage